Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Third Quarter Earnings Conference Call on Thursday, November 12, 2009 at 9:30 a.m. ET

Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Third Quarter Earnings
Conference Call on Thursday, November 12, 2009 at 9:30 a.m. ET

XIANYANG, China, Nov. 9 /PRNewswire-Asia-FirstCall/ -- Biostar
Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM) ("Biostar" or "the Company"),
a Xianyang-based developer, manufacturer and supplier of pharmaceutical
products and medical nutrients addressing a variety of diseases and
conditions,
today announced that management will hold a conference call to discuss its
2009 third quarter performance at 9:30 a.m. ET on Thursday, November 12, 2009.
Financial results will be released on November 11, 2009 after the market
closes.
Interested parties may access the call by dialing +1-888-549-7704 from
within the United States, or +1-480-629-9857 if calling internationally. The
conference ID is 4182017. It is advisable to dial in approximately 5-10
minutes prior to the start of the call.
This call is being web cast by ViaVid Broadcasting and can be accessed at
ViaVid's website at http://www.viavid.net or at the following link:
http://viavid.net/dce.aspx?sid=00006CE5 . To access the web cast, you will
need to have the Windows Media Player on your desktop. For the free download
of the Media Player please visit:
http://www.microsoft.com/windows/windowsmedia/en/download/default.asp .
About Biostar Pharmaceuticals, Inc.
Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary in
China, develops, manufactures and markets pharmaceutical and medical nutrient
products for a variety of diseases and conditions. The Company's most popular
product is its Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter ("OTC")
medicine for chronic hepatitis B, a disease affecting approximately 10% of the
Chinese population. In addition to its hepatitis product, Biostar
manufactures two broad-based OTC products, two prescription-based
pharmaceuticals and ten nutrients. The Company has adopted international
standards and is in the process of applying for three patents.
Safe Harbor
Certain statements in this release concerning our future growth prospects
are forward-looking statements, within the meaning of Section 27A of the U.S.
Securities Act of 1933, as amended, and Section 21E of the U.S. Securities
Exchange Act of 1934, as amended, which involve a number of risks and
uncertainties that could cause actual results to differ materially from those
in such forward-looking statements. The risks and uncertainties relating to
these statements include, but are not limited to, risks and uncertainties
regarding the success of our investments, risks and uncertainties regarding
fluctuations in earnings, our ability to sustain our previous levels of
profitability including on account of our ability to manage growth, intense
competition, wage increases in China, our ability to attract and retain highly
skilled professionals, time and cost overruns on fixed-price, fixed-time frame
contracts, client concentration, our ability to successfully complete and
integrate potential acquisitions, withdrawal of governmental fiscal
incentives,
political instability and regional conflicts and legal restrictions on raising
capital or acquiring companies outside China. Additional risks that could
affect our future operating results are more fully described in our United
States Securities and Exchange Commission filings including our S-1 dated June
27, 2008, our Quarterly Report on Form 10-Q for the quarter ended June 30,
2009, our 10-K for the year ended December 31, 2008, and other recent filings.
These filings are available at http://www.sec.gov . We may, from time to
time,
make additional written and oral forward-looking statements, including
statements contained in our filings with the Securities and Exchange
Commission and our reports to shareholders. We do not undertake to update any
forward-looking statements that may be made from time to time by or on our
behalf.
For further information, please contact:

Ms. Elaine Zhao, CFO
Tel: +1-626-456-2789
Email: elaine@biostarpharmaceuticals.com

John Mattio
HC International, Inc.
Tel: US +1-914-669-5340
Email: john.mattio@hcinternational.net
Web: http://www.hcinternational.net

SOURCE Biostar Pharmaceuticals, Inc.

Ms. Elaine Zhao, CFO of Biostar, +1-626-456-2789, or
elaine@biostarpharmaceuticals.com; or John Mattio of HC International, Inc.,
+1-914-669-5340, or john.mattio@hcinternational.net, for BSPM